Xiaoqing Boynton is a Partner at DGA-Albright Stonebridge Group, a founding member of DGA Group, and is based in Washington, D.C.  As a member of the firm’s China practice, she advises clients on market entry and expansion, risk management, and government relations regarding the China market. 

Ms. Boynton brings more than two decades of experience working on U.S.-China issues to help clients navigate the complex political and regulatory environment. Most recently, she served as Senior Director for International Affairs at the Biotechnology Innovation Organization (BIO), the world’s largest biotech association, where she was responsible for BIO’s advocacy strategy in Asia, including China and Japan. She worked closely with BIO board and member companies to promote an ecosystem for innovation. Previously, Ms. Boynton was a Vice President in Albright Stonebridge Group. Before that, she served as a Fellow at the Center for Strategic and International Studies, where she led projects on Chinese socioeconomic issues and global health. She also consulted for Eurasia Group and Global Health Strategies on health security and industry regulations in Asia. Early in her career, she worked at the American Bar Association’s Asia Law Initiative in Beijing.

Ms. Boynton has been interviewed on U.S.-China and healthcare issues by news outlets including Bloomberg, NPR and the Wall Street Journal, and has testified before the U.S.-China Economic and Security Review Commission.

Ms. Boynton holds an M.A. in international development from Brandeis University and a B.A. in international economics and trade from Beijing Second Foreign Language University. She is fluent in Mandarin Chinese.